LOY-002 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
LOY-002 is a daily pill for older dogs that could become the first drug the FDA approves to extend lifespan. The FDA accepted its safety and effectiveness sections in 2025 and 2026.
Evidence grade for LOY-002: Animal or lab only. The rule: only animal or lab studies on this page. No study in people yet. The sum on this page: 2 animal studies, no human study. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
2 animal studies, no human study
1 effects reported, 1 unwanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
LOY-002 is a daily pill for dogs aged ten and older, made by Loyal. It is meant to extend a dog's life. It could become the first drug the FDA has ever approved for that. It is not for people.
What people take it for
- Helping an older dog live longer.
- Showing that lifespan can be a drug target.
What studies in people showed
There are no published results. The FDA accepted the section saying it can reasonably be expected to work in February 2025, and the safety section in January 2026. The main study signed up 1,300 dogs at 70 clinics. Approval could come in late 2026 or 2027.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- No study results have been published yet.
Where these come from: Everything here is from the Loyal releases on this page. There are no user reports.
My bottom line
It is a dog drug. Do not take it. If it works, that will matter for the whole field.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 2 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is LOY-002?
LOY-002 is a daily pill for older dogs that could become the first drug the FDA approves to extend lifespan. The FDA accepted its safety and effectiveness sections in 2025 and 2026.
LOY-002 is a daily pill from Loyal for dogs aged ten and older. It is meant to fix the changes in how the body handles fuel that come with age. The FDA's animal drug center accepted the section showing it can reasonably be expected to work in February 2025, and the safety section in January 2026. Both were firsts for a lifespan drug. The main study, STAY, signed up 1,300 dogs at 70 clinics. Conditional approval could come in late 2026 or 2027. The exact target of the drug has not been made public. It is not for people.
How does LOY-002 work?
Not made public. The company says it corrects changes in how the body handles fuel that come with age.
The evidence, in charts
Fig. 1a · how many people
0people have taken this in any study cited here
0 people · 0 studies in people
What this page cites instead is 2 animal studies. None of them gave the compound to a person.
Counted from the list of sources on this page. We draw this chart only when a study in people is cited. An empty one is the answer, not a gap in the page.
Fig. 1b · evidence mix
None of the 2 sources here are studies in people.
- Animal study · done in animals2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2025 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- Not disclosed
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for LOY-002, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Animal study2026Loyal receives FDA acceptance of safety package for senior dog lifespan extension drug
In dogs: the FDA accepted the safety section for this lifespan drug, a first for any drug of its kind. This is a regulator's decision, not a published study.
First safety acceptance for any lifespan drug.
- Animal study2025Loyal receives FDA acceptance of reasonable expectation of effectiveness
In dogs: the FDA agreed the drug can reasonably be expected to extend lifespan. That is a regulator's view of the company's data, not a published result.
Regulator agreed the drug could plausibly extend lifespan.
Common questions
Has LOY-002 been tested in people?
Not in any study cited here. LOY-002 is a daily pill for older dogs that could become the first drug the FDA approves to extend lifespan. The FDA accepted its safety and effectiveness sections in 2025 and 2026.
What is the LOY-002 dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 2 animal studies, no human study
Is LOY-002 FDA-approved?
On a conditional-approval path as an animal (veterinary) drug; not for humans
Why is a dog drug on a human longevity site?
Because a regulator agreeing that lifespan can be what a drug is judged on is a milestone for the whole field. The same age-related changes in how the body handles fuel sit behind GLP-1 and mTOR research in people.